https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1242970/full
Frontiers | CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing...
Background: Interleukin-2 (IL-2) is the first cancer therapeutic agent with an immunomodulatory function. Although it has been experimentally proven to be ef...